Recent extremely meaningful positive changes in investment behavior have benefitted Regeneron Pharmaceuticals Inc (NASDAQ: REGN): positive upside/downside volume developed, and the stock’s recent price rise disrupted its longer term downtrend.
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has recently enjoyed notable positive changes in fundamentals: significant quarterly earnings acceleration occurred, and the stock’s power rating rose above 70.
In light of these very positive signals we are reviewing our current Overall Rating of B. We would continue to view the shares with optimism pending completion of this review in the next several days.
Current PriceTarget Research Rating
REGN’s future returns on capital are forecasted to be above the cost of capital. Accordingly, the company is expected to continue to be an important Value Builder.
Regeneron Pharmaceuticals has a current Value Trend Rating of B (Positive). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Regeneron Pharmaceuticals has a neutral Appreciation Score of 60 but a good Power Rating of 72, producing the Positive Value Trend Rating.
Recent Price Action
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) stock declined modestly by -1.6% on 7/15/24. The stock closed at $1082.11. This decline was accompanied by normal trading volume. The stock has been strong relative to the market over the last nine months and has risen 4.6% during the last week.
Be the first to comment